Pneumococcal 21-valent Conjugate Vaccine

(Capvaxive®)

Pneumococcal 21-valent Conjugate Vaccine

Drug updated on 10/17/2024

Dosage FormInjection (intramuscular; 0.5 mL)
Drug ClassVaccine
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in individuals 18 years of age and older
  • Indicated for active immunization for the prevention of pneumonia caused by S
  • pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in individuals 18 years of age and older.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of one randomized controlled trial(s). [1]
  • V116 met non-inferiority criteria compared to PPSV23 for the 12 shared serotypes, with serotype-specific opsonophagocytic antibody geometric mean titres (OPA (Opsonophagocytic Activity)-GMT (Geometric Mean Titer)) ratios measured at 30 days post-vaccination, and demonstrated superiority over PPSV23 for the nine unique serotypes.
  • In healthy adults aged 18-49 (Phase 1) and those aged 50 or older (Phase 2), V116 showed consistent effectiveness, achieving both non-inferiority for shared serotypes and superiority for unique serotypes.
  • Both age groups demonstrated similar trends in immunogenicity, supporting the potential effectiveness of V116 in preventing pneumococcal disease in adults.
  • No vaccine-related serious adverse events or deaths were reported in either phase of the study. The most common adverse event was injection site pain, occurring in 73-77% of V116 recipients in Phase 1 and 46% in Phase 2, compared to 57% and 38% for PPSV23.
  • Systemic adverse events like fatigue and myalgia were more common with V116 than PPSV23, with fatigue reported by 27% of V116 recipients in Phase 1 and 19% in Phase 2, compared to 17% and 12% for PPSV23. Most adverse events were mild and resolved within 3 days.
  • There is no population types or subgroups information available in the reviewed studies.